绿麦cognitaven®通过激活CREB/BDNF/Nrf2/HO-1通路和调节NF-κB/MAPK信号传递来减轻轻度的认知障碍
Rengasamy Balakrishnan1, Yon-Suk Kim2, Shin-Il Kang3
1Department of Applied Life Sciences, Graduate School, BK21 Program, Konkuk University, Chungju 27478, South Korea; Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, South Korea.
概括
绿麦cognitaven®显示神经保护和抗炎作用,通过改善记忆和减少神经炎症,可能有助于阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 管理.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 营养科学 营养科学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,治疗选择有限.
- 轻度认知障碍 (MCI) 通常在AD之前,表明早期认知衰退和记忆功能障碍.
- 阿尔茨海默病的复杂病原体需要新的治疗策略,包括针对神经炎症的治疗策略.
研究的目的:
- 为了研究绿麦cognitaven®的神经保护和抗炎作用.
- 评估绿子cognitaven®在缓解与AD相关的认知缺陷和神经炎症方面的潜力.
- 在体外和体内探索绿麦cognitaven®作用的潜在分子机制.
主要方法:
- 在体外:用绿麦cognitaven®治疗的LPS刺激的BV-2微质细胞.
- 在体内:斯科波胺诱导的失忆老鼠模型口服绿麦cognitaven®.
- 对炎症标记物,信号通路 (NF-κB/MAPK) 和神经保护生物标记物的分析 (p-CREB,BDNF,Nrf2/HO-1).
主要成果:
- 绿子cognitaven®抑制了微质细胞中的氧化 (NO) 释放和炎症反应.
- 它抑制了NF-κB和MAPK信号通路,减少了神经炎症.
- 在丧失记忆的小鼠中,它防止了空间学习和记忆障碍,并提高了p-CREB和BDNF的调节.
- 观察到Nrf2/HO-1表达的升级和NF-κB/MAPK信号的抑制.
结论:
- 绿麦cognitaven®具有显著的抗神经炎症和神经保护性质.
- 它有效地减轻了记忆丧失的动物模型中的认知缺陷.
- 绿麦Cognitaven®证明了对管理AD相关的MCI的治疗潜力.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
213
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
213
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
Antiepileptic Drugs: GABAergic Pathway Potentiators
671
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
671


